Gene · 200576
PIKFYVE: phosphoinositide kinase, FYVE-type zinc finger containing
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PIKFYVE: phosphoinositide kinase, FYVE-type zinc finger containing. Genes, record 200576. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/200576
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9Y2I7 | 1-phosphatidylinositol 3-phosphate 5-kinase | 2,098 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents15
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026515744 A | 2026-05-19 | 375 | Q9Y2I7 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 57860 | Q9Y2I7 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2344 | Q9Y2I7 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1912 | Q9Y2I7 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1912 | Q9Y2I7 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2344 | Q9Y2I7 | Espacenet |
| WO 2024214081 A1 | 2024-10-17 | 375 | Q9Y2I7 | Espacenet |
| JP 2022141755 A | 2022-09-29 | 213 | Q9Y2I7 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 63131 | Q9Y2I7 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 166102 | Q9Y2I7 | Espacenet |
1 to 10 of 15
See all 15 patentsDrugs3
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| APILIMOD | CHEMBL18144 | 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor | INHIBITOR | ChEMBL |
| APILIMOD | CHEMBL4297643 | 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor | INHIBITOR | ChEMBL |
| APILIMOD MESYLATE | CHEMBL6067997 | 1-phosphatidylinositol 3-phosphate 5-kinase inhibitor | INHIBITOR | ChEMBL |
Trials10
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05483322 | APILIMOD | ClinicalTrials.gov | ||
| NCT05483322 | APILIMOD | ClinicalTrials.gov | ||
| NCT05163886 | APILIMOD MESYLATE | PHASE2 | ClinicalTrials.gov | |
| NCT02594384 | APILIMOD MESYLATE | PHASE1 | 2024-08-22 | ClinicalTrials.gov |
| NCT00642629 | APILIMOD MESYLATE | PHASE2 | ClinicalTrials.gov | |
| NCT00263237 | APILIMOD MESYLATE | PHASE1 | ClinicalTrials.gov | |
| NCT00250198 | APILIMOD MESYLATE | PHASE2 | ClinicalTrials.gov | |
| NCT00234741 | APILIMOD MESYLATE | PHASE2 | ClinicalTrials.gov | |
| NCT00138840 | APILIMOD MESYLATE | PHASE2 | ClinicalTrials.gov | |
| NCT00088062 | APILIMOD | PHASE1/PHASE2 | ClinicalTrials.gov |
NIH grants1,374
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PIKFYVE papers | Newest fiscal year |
|---|---|---|---|
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 10 | 2025 |
| R35GM119412 | Directing Membrane Function with Inositol Lipids in Health and Disease | 9 | 2025 |
| R35GM130386 | Cell Biology of Endosomal Escape | 9 | 2025 |
| ZIAHD000196 | Phosphoinositide-calcium Signaling In Cell Regulation | 9 | 2025 |
| U19AI135972 | SARS-CoV adaptations through a Systems Biology Lens (SYBIL) | 8 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 5 | 2025 |
| P30DA018343 | Yale/NIDA Neuroproteomics Center | 5 | 2025 |
| R01GM088790 | Functional architecture of intracellular Ca2+ signals | 5 | 2025 |
| T32CA009054 | A Training Program for Interdisciplinary Cancer Research | 5 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 4 | 2025 |
1 to 10 of 1,374Source NIH's project files
See all 1,374 nih grantsPapers1,790
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PI(3,5)P2 controls the signaling activity of class I PI3K. | Sci Adv | 2026 | 42814813 | PubTator, text mining | PubMed |
| JAK3 regulates PIP5K expression, promotes PIP2 generation and Ca2+ driven platelet activation in arterial thrombosis. | Blood | 2026 | 42766692 | PubTator, text mining | PubMed |
| Novel mutations of PIKFYVE identified in 322 sporadic cataract patients. | Ophthalmic Genet | 2026 | 42717816 | PubTator, text mining | PubMed |
| Targeting PIKfyve: Chemical Biology and Drug Discovery Insights. | Chem Biol Drug Des | 2026 | 42681571 | PubTator, text mining | PubMed |
| Ion transport as a determinant of membrane fusion and fission. | Nat Struct Mol Biol | 2026 | 42618799 | PubTator, text mining | PubMed |
| Synthesis and evaluation of 3,5-disubstituted isothiazolo[4,5-b]pyridines, pyrazolo[4,3-b]pyridines and isothiazolo[3,4-b]pyrazines as inhibitors of PIKfyve. | Bioorg Chem | 2026 | 42570378 | PubTator, text mining | PubMed |
| Quantitative comparison of PI(3,5)P2 biosensors reveals SnxA is the most sensitive and unbiased. | Mol Biol Cell | 2026 | 42555823 | PubTator, text mining | PubMed |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | 42546705 | PubTator, text mining | PubMed |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | 42528528 | PubTator, text mining | PubMed |
| PI4K and PIPK families in breast cancer: subtype-specific oncogenic mechanisms and precision therapeutic strategies. | Mol Biol Rep | 2026 | 42455373 | PubTator, text mining | PubMed |
1 to 10 of 1,790
See all 1,790 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/200576
GET https://conductscience.org/api/genes/v1/200576/patents